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DISCUSSION: The majority of people that were treated
with statins stayed on these drugs although they used less
than was prescribed to them. Adherence to statins in-
creased over the years, however patients became less adher-
ent the longer they used them.
PCV11
STUDY OF HEALTH CARE RESOURCE USE FOR 
ELDERLY PATIENTS WITH MILD AND 
MODERATE ARTERIAL HYPERTENSION
Geltzer B, Frisman M
Vladivostok State Medical University, Vladivostok, Russia
OBJECTIVES: To study health care expenditures for pa-
tients with arterial hypertension.
METHODS: We observed elderly patients (n  186; mid-
dle age 68,4  2,2 years) from January 1997 to May 1999.
We investigated four medicines from the basic groups of
hypotensive drugs: nifedipine-GITS; enalapril; diltiazem;
indapamide. We defined duration of hospital treatment,
number of ambulant visits and emergency care.
RESULTS: Before treatment the middle number of ambu-
lant visits was 6,01 per year. Against a background of
monotherapy the number of visits was decreased: in nife-
dipine-GITS group (NG)—to 2,75 (CI 1,2–2,4); in enala-
pril group (EG)—to 3,27 (CI 1,5–3,1); in diltiazem group
(DG)—to 3,76 (CI 1,4–2,3); in indapamide group (IG)—to
5,28 (CI 1,4–3,2). Expenditures of health care were dimin-
ished: in NG—by 54,53%; in EG—by 46,14%; in DG—by
37,82%; in IG—by 12,69%. Before the treatment the mid-
dle duration of hospital treatment was 22,84 days. Against
a background of monotherapy the duration of hospital
treatment was decreased: in NG—to 14,25 days (CI 1,74–
3,48); in EG—to 16,63 days (CI 1,35–3,21); in DG—to
15,76 days (CI 1,42–3,38); in IG—to 16,57 days (CI 1,41–
3,23). Expenditures of health care were diminished: in
NG—by 37,62%; in EG—by 27,2%; in DG—by 31,01%;
in IG—by 27,47%. Combined economy in NG was
48,2%; in EG—27,76%; in DG—36,61%; in IG—32,3%.
RESULTS: This investigation provides comparative evalu-
ation of economy of health care resource with different
medicines.
PCV12
ECONOMIC EVALUATION OF ACE INHIBITORS 
IN SPAIN
Asensio J, Hermida H, Abbas I
Kendall Institute, Barcelona, Spain
OBJECTIVES: To evaluate which ACE inhibitor, of the
10 that are marketed in Spain, offers the most favorable
cost-effectiveness relationship in the treatment of light-
moderate arterial HBP.
MATERIAL AND METHODS: Only direct costs derived
from treatment were taken into consideration. We have
calculated the cost of treatment per day (CTD) in the fol-
lowing way: By grouping the different pharmaceutical
products marketed in Spain by active ingredients. The price
of the daily defined dose (DDD) was established for each
product by dividing its price by the number of tablets that
the DDD requires in accordance with the recommended
dose in the information leaflet.
RESULTS: In more or less objective terms it is accepted
that therapeutic efficiency within the group of ACE inhibi-
tors is very similar and so efficiency depends exclusively on
the cost of the product. This has lead to the carrying out of
an analysis of the minimization of costs, and this shows
that the alternative with the lowest cost per controlled pa-
tient is Enalapril, so substituting this option for the rest of
ACE inhibitor prescriptions could result in very significant
savings. Potential savings could reach 10,801 Million Ptas.
per annum if the lower priced Enalapril were used.
CONCLUSIONS: Enalapril is the most cost-effective ACE
inhibitor for the treatment of light and moderate HBP in
Spain. Substituting Enalapril for prescriptions for the rest
of ACE inhibitors could lead to a significant saving poten-
tial in pharmaceutical spending. Changing to lower priced
Enalapril could increase the figure for potential savings by
up to almost 11,000 Million Ptas. per annum which makes
it the most efficient option.
ECONOMIC AND OUTCOMES ISSUES OF 
ENDOCRINE DISORDERS
PEN1
QUALITY-OF-LIFE-EVALUATION OF THE 
GERMAN S.A.T.-TRIAL - COMPARISON OF SF-36, 
EUROQOL, TIME-TRADE-OFF METHOD AND 
WILLINGNESS-TO-PAY
Wendland G, Kurscheid T, Lauterbach KW
University of Cologne, Köln, Germany
OBJECTIVE: To assess the effectiveness of evidence-based
treatment of obesity in a primary care setting, we con-
ducted the S.A.T.-trial (Sibutramine in Adiposity Trial)
which is a multicenter, double-blind, placebo-controlled,
randomized parallel group comparison of 54-week contin-
uous therapy with Sibutramine 15 mg or Placebo in addi-
tion to a standardized non-pharmacological therapy con-
sisting of a calorie-restricted diet, modification of eating
behavior and lifestyle, and an activity programme. Patients
with a BMI between 30 and 40 are included. The primary
endpoint in this study is weight loss in kg between the last
measurement of body weight (visit 11) and the measure-
ment at the first visit. Secondary endpoints are amongst
other clinical parameters health economic and quality of
life data. Since the random code is still not broken, the re-
sults given in this abstract refer to all randomized obese
patients in the study (both Sibutramine and placebo
group). The presentation in November will show the re-
sults for the two patient groups separately.
QUALITY OF LIFE MEASURES: Quality of life is mea-
sured by 4 different instruments: the Short Form 36 (SF-36):
the EuroQol, the Time-trade-off-Method (TTO) and the
Willingness-to-pay-Method (WTP). The SF-36 is a general,
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standardized and validated Quality-of-life-instrument, con-
sisting of 36 questions that can be aggregated into 8 health
dimensions. The EuroQol is also a general, standardized
and validated quality-of-life-questionnaire, having the ad-
vantage of aggregating the five health dimensions into one
quality-of-life-index. Therefore, the EuroQol is frequently
used in health economic evaluations to calculate Quality ad-
justed life years saved (QALYs). In the TTO interview pa-
tients are asked questions to calculate a quality-of-life-index
for each patient stratified by age. In the willingness-to-pay-
questionnaire, obese patients are asked how much they
would be prepared to pay per month for an immediate and
sustained weight loss of 10 kg from their current body
weight. The answers are stratified by net income classes.
RESULTS: Quality of life measured by the SF 36 has im-
proved in all 8 health dimensions at visit 2 compared to
visit 1. Especially energy/fatigue is impaired in obese pa-
tients. The quality-of-life-index measured by the EuroQol
has slightly improved from visit 1 to visit 2 over all age-
groups. The quality-of-life-index of the TTO-interview
and the EuroQol-questionnaire are very similar except for
the age group 35 years. Willingness-to-pay correlates
positively with net income.
DISCUSSION: The results are preliminary, but in line with
the published literature. They reveal the massive burden of
obese patients.
PEN2
METHODOLOGICAL ASPECTS OF MULTI-
COUNTRY COST OF ILLNESS STUDIES—2: 
INTERNET BASED DATA MANAGEMENT
Kirsch J1, Wilfling M2, Elfering I2, Hood S1
1Health Economics Dept., SmithKline Beecham 
Pharmaceuticals, Harlow, Essex, UK; 2MedicalData Service, 
Münster, Germany
OBJECTIVE: Managing the data collected in multi-country
cost of illness studies is a major task. The objective of this
task is to ensure the accuracy and confidentiality of the data
collected and to provide a flexible platform for analysis.
METHOD: The CODE-2* (Costs of Diabetes in Europe
type 2) study was conducted simultaneously in 8 European
countries to evaluate the total burden of type 2 diabetes.
Resource utilisation, clinical and demographic data were
collected using specifically designed data collection instru-
ments. Over 3 million discrete items of data relating to over
7000 patients were collected and entered, transmitted and
stored within a centralized database. This was achieved us-
ing HTML and XML programming and software technol-
ogy as the basis for data entry and data file creation and
IDT** encryption techniques to ensure data privacy for
data sent via the Internet to a central server database. These
novel systems offer a number of advantages such as: user
friendly data entry screens, on line data validation, ‘limit-
less’ data entry for certain resource items (e.g., practitioner
visits), on line program updates, exception data reports, file
status reports, confidential data transfer, central data vali-
dation, derived variable creation, on line analytics and
progress reports, and data export functionality to analyti-
cal packages such as SAS, SPSS and Excel.
RESULTS: As a result of using this data management ap-
proach, a consistent and high quality data set for analysis
was assured for the CODE-2 study.
CONCLUSIONS: Internet technology, such as that used in
the CODE-2 study, should have a greater role to play in the
collection and management of data in future multi-country
cost of illness studies. *Registered Trademark of SmithKline
Beecham. **Registered Trademark of MDS.
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DEVELOPMENT OF AN ALGORITHM FOR 
ESTIMATING ASTHMA SEVERITY FROM AN 
ADMINISTRATIVE COST DATABASE
Leidy NK1, Paramore LC1, Watrous M2, Doyle J3, Zeiger RS4
1MEDTAP International, Bethesda, MD, USA; 2Genentech, Inc., 
South San Francisco, CA, USA; 3Novartis Pharmaceuticals 
Corporation, East Hanover, NJ, USA; 4Kaiser Permanente, San 
Diego, CA, USA
OBJECTIVES: The purpose of this study was to develop
and test an algorithm for estimating disease severity for
economic studies involving administrative cost database
analyses. The intent was to go beyond the traditional
three-group classification (mild, moderate, severe) and de-
velop a more refined four-group system consistent with
NHLBI Guidelines for estimating asthma severity: mild in-
termittent (MI), mild persistent (MP), moderate persistent
(MoP), severe persistent (SP).
METHODS: A retrospective cohort design was used, em-
ploying administrative claims from a fee-for-service pro-
vider of health care benefits to approximately 3.5 million
federal employees in the U.S. Patients with asthma were
defined by: 
1 medical encounters for asthma (exclusive
of COPD and allergic rhinitis) during 1994–5 and continu-
ous enrollment in the health plan for 24 months; 22,833
patients with asthma were identified. Four algorithms
were developed using NHLBI guidelines for pharmaco-
logic intervention with adjustments for practice patterns
during 1994-5. Evaluation was based on the observed se-
verity distribution in the population and results from bi-
variate and multivariate analyses in random samples, ex-
amining the relationship between severity level and the
following clinically-grounded variables: deaths, hospital-
izations, ER visits, and use of an allergist/pulmonologist.
RESULTS: The final algorithm was a 2-step procedure
based on -2 agonist and oral steroid use. Severity distri-
bution in the population was as follows: 69.5% MI,
16.9% MP, 11.1% MoP, and 2.5% SP. The final, popula-
tion-based bivariate analyses showed a logical stair-step
pattern with significant relationships between severity and
death rates, number of hospitalizations, and specialist use
(p  .001). The ordinal logistic regression model was also
significant (p  .0001; chi-square  597.45, df  4), with
a Goodman-Kruskal Gamma statistic of 0.25.
CONCLUSION: Results suggest the algorithm is useful
for classifying patients into four levels of severity using an
